High-Throughput Chemical Screening and Structure-Based Models to Predict hERG Inhibition

被引:12
|
作者
Krishna, Shagun [1 ]
Borrel, Alexandre [2 ]
Huang, Ruili [3 ]
Zhao, Jinghua [3 ]
Xia, Menghang [3 ]
Kleinstreuer, Nicole [1 ]
机构
[1] NIEHS, Div Natl Toxicol Program, Res Triangle Pk, NC 27560 USA
[2] Silent Spring Inst, Newton, MA 02460 USA
[3] Natl Ctr Adv Translat Sci NCATS, Div Preclin Innovat, Bethesda, MD 20892 USA
来源
BIOLOGY-BASEL | 2022年 / 11卷 / 02期
基金
美国国家卫生研究院;
关键词
cardiovascular; hERG; Tox21 high-throughput screening; environmental chemicals; in silico modeling; QSAR models; POTASSIUM CHANNEL BLOCKAGE; CARDIAC-ARRHYTHMIA; DRUGS; DISINFECTANTS; PROLONGATION; TERFENADINE; MECHANISM; AFFINITY; INTERVAL; BROMIDE;
D O I
10.3390/biology11020209
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Simple Summary Cardiovascular disease is the leading cause of death for people of most ethnicities in the United States. The human ether-a-go-go-related gene (hERG) potassium channel plays a pivotal role in cardiac rhythm regulation, and cardiotoxicity associated with hERG inhibition by drug molecules and environmental chemicals is a major public health concern. An evaluation of the effect of environmental chemicals on hERG channel function can help inform the potential public health risks of these compounds. To assess the cardiotoxic effect of diverse drugs and environmental compounds, the Tox21 federal research program has screened a collection of 9667 chemicals for inhibitory activity against the hERG channel. A set of molecular descriptors covering physicochemical and structural properties of chemicals, self-organizing maps, and hierarchical clustering were applied to characterize the chemicals inhibiting hERG. Machine learning approaches were applied to build robust statistical models that can predict the probability of any new chemical to cause cardiotoxicity via this mechanism. Chemical inhibition of the human ether-a -go-go-related gene (hERG) potassium channel leads to a prolonged QT interval that can contribute to severe cardiotoxicity. The adverse effects of hERG inhibition are one of the principal causes of drug attrition in clinical and pre-clinical development. Preliminary studies have demonstrated that a wide range of environmental chemicals and toxicants may also inhibit the hERG channel and contribute to the pathophysiology of cardiovascular (CV) diseases. As part of the US federal Tox21 program, the National Center for Advancing Translational Science (NCATS) applied a quantitative high throughput screening (qHTS) approach to screen the Tox21 library of 10,000 compounds (~7871 unique chemicals) at 14 concentrations in triplicate to identify chemicals perturbing hERG activity in the U2OS cell line thallium flux assay platform. The qHTS cell-based thallium influx assay provided a robust and reliable dataset to evaluate the ability of thousands of drugs and environmental chemicals to inhibit hERG channel protein, and the use of chemical structure-based clustering and chemotype enrichment analysis facilitated the identification of molecular features that are likely responsible for the observed hERG activity. We employed several machine-learning approaches to develop QSAR prediction models for the assessment of hERG liabilities for drug-like and environmental chemicals. The training set was compiled by integrating hERG bioactivity data from the ChEMBL database with the Tox21 qHTS thallium flux assay data. The best results were obtained with the random forest method (~92.6% balanced accuracy). The data and scripts used to generate hERG prediction models are provided in an open-access format as key in vitro and in silico tools that can be applied in a translational toxicology pipeline for drug development and environmental chemical screening.
引用
收藏
页数:26
相关论文
共 50 条
  • [21] Surrogate docking: structure-based virtual screening at high throughput speed
    Yoon, S
    Smellie, A
    Hartsough, D
    Filikov, A
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2005, 19 (07) : 483 - 497
  • [22] Structure-based virtual high throughput screening for enzyme optimization.
    Dahiyat, BI
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U381 - U381
  • [23] Surrogate docking: structure-based virtual screening at high throughput speed
    Sukjoon Yoon
    Andrew Smellie
    David Hartsough
    Anton Filikov
    Journal of Computer-Aided Molecular Design, 2005, 19 : 483 - 497
  • [24] Evaluation of a high-throughput fluorescence assay method for hERG potassium channel inhibition
    Dorn, A
    Hermann, F
    Ebneth, A
    Bothmann, H
    Trube, G
    Christensen, K
    Apfel, C
    JOURNAL OF BIOMOLECULAR SCREENING, 2005, 10 (04) : 339 - 347
  • [25] Use of high-throughput nanovolume crystallization in structure-based drug design.
    Stafford, JA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U460 - U461
  • [26] High-throughput x-ray crystallography for structure-based drug design
    Goodwill, KE
    Tennant, MG
    Stevens, RC
    DRUG DISCOVERY TODAY, 2001, 6 (15) : S113 - S118
  • [27] The genesis of high-throughput structure-based drug discovery using protein crystallography
    Kuhn, P
    Wilson, K
    Patch, MG
    Stevens, RC
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (05) : 704 - 710
  • [28] Development of a Thyroperoxidase Inhibition Assay for High-Throughput Screening
    Paul, Katie B.
    Hedge, Joan M.
    Rotroff, Daniel M.
    Hornung, Michael W.
    Crofton, Kevin M.
    Simmons, Steven O.
    CHEMICAL RESEARCH IN TOXICOLOGY, 2014, 27 (03) : 387 - 399
  • [29] High-throughput screening - Reliability issues in high-throughput screening systems
    Brandt, DW
    BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT, 1998, 11 (02): : 30 - +
  • [30] Structure-based tailoring of compound libraries for high-throughput screening: Discovery of novel EphB4 kinase inhibitors
    Kolb, Peter
    Kipouros, Catherine Berset
    Huang, Danzhi
    Caflisch, Amedeo
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2008, 73 (01) : 11 - 18